Vyvanse (lisdexamfetamine
dimesilate) has been launched in
Australia by Shire Pharmaceuticals,
having been TGA-approved for the
treatment of ADHD.
It’s the first pro-drug stimulant to
be approved in Australia for ADHD
and provides long-acting efficacy of
up to 13-14 hours.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Aug 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.